The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
The Efficacy and Safety of Rifaximin for the Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis
Abstract
OBJECTIVES: Irritable bowel syndrome (IBS) affects 10-15% of the population, and treatment options are limited. Rifaximin is a minimally absorbed antibiotic that has shown efficacy in IBS patients. The objective of our study was to perform a meta-analysis and systematic review of available randomized, placebo controlled trials evaluating the efficacy and tolerability of rifaximin in patients with IBS. METHODS: We performed a systematic literature search of multiple online electronic databases regardless of language. Inclusion criteria entailed randomized, placebo controlled trials and IBS defined by accepted symptom-based criteria. Meta-analysis was conducted to evaluate the summary odds ratios (ORs) and 95% confidence intervals (CIs) of combined studies for the primary and secondary outcomes using a random-effects model based on the DerSimonian and Laird method to reflect both within- and between study variability. We assessed heterogeneity using χ(2) test and the inconsistency index statistic (I(2)). Significant heterogeneity was defined as I(2) ≥25%. Meta-regression was performed using generalized linear mixed-effects model and study as random effects to estimate the summary OR adjusting for covariate differences across studies and treatment group. Publication bias was assessed by funnel plot analysis. RESULTS: Systematic review identified 13,700 citations. Eighteen were deemed to be potentially relevant, of which five articles met eligibility. Meta-analysis found rifaximin to be more efficacious than placebo for global IBS symptom improvement (OR=1.57; 95% CI=1.22, 2.01; therapeutic gain=9.8%; number needed to treat (NNT)=10.2), with mild heterogeneity (P=0.25, I(2)=26%). For the key secondary outcome of bloating, raw data were available for four studies. Rifaximin was significantly more likely to improve bloating than placebo (OR=1.55; 95% CI=1.23-1.96; therapeutic gain=9.9%; NNT=10.1), with no significant heterogeneity (P=0.27, I(2)=23%). We found that studies with older patients and more females demonstrated higher response rates, which was consistent regardless of treatment group. In addition, studies with higher cumulative dose tended to report a higher response rate. Of the covariates evaluated, we found age to be most predictive of response, with a correlation coefficient of 0.97 between aggregate response rate and mean age in the placebo groups. Although studies with higher cumulative dose tended to show increased response rates, this was also seen consistently in both the treated and placebo groups. Adverse effects were similar among patients receiving rifaximin or placebo in all studies. The most common adverse events (AEs) (≤10%) with rifaximin were headache, upper respiratory infection, nausea, nasopharygitis, diarrhea, and abdominal pain. Serious AEs were rare (<1%) and similar with rifaximin and placebo. CONCLUSIONS: Rifaximin proved more effective than placebo for global symptoms and bloating in IBS patients. The modest therapeutic gain was similar to that yielded by other currently available therapies for IBS. AEs were similar between rifaximin and placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“available metanalysis tend to show a beneficial profile of rifaximin vs placebo on global IBS symptoms and bloating [291]”
From Gut microbiota role in irritable bowel syndrome: New therapeutic strategies (2016) · cites this paper as [291]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Self-citationDrossman, D. A., Li, Z., Andruzzi, E., Temple, R. D., Talley, N. J., Grant Thompson, W., Whitehead, W. E., Janssens, J., Funch-Jensen, P., Corazziari, E., et al. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01303162 · Cited by 2,198
COMT val 158 met Genotype Affects µ-Opioid Neurotransmitter Responses to a Pain Stressor
Zubieta, J.-K., Heitzeg, M. M., Smith, Y. R., Bueller, J. A., Xu, K., Xu, Y., Koeppe, R. A., Stohler, C. S., & Goldman, D. A. (2003) · Science · doi:10.1126/science.1078546 · Cited by 1,128
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036
Self-citationKassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002
Altered rectal perception is a biological marker of patients with irritable bowel syndrome
Mertz, H., Naliboff, B. D., Munakata, J., Niazi, N., & Mayer, E. A. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90267-8 · Cited by 976
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833
Eradication of Small Intestinal Bacterial Overgrowth Reduces Symptoms of Irritable Bowel Syndrome
Pimentel, M., Chow, E. J., & Lin, H. C. (2000) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.03368.x · Cited by 780
Gender Differences in Treatment Response to Sertraline Versus Imipramine in Chronic Depression
Kornstein, S. G., Schatzberg, A. F., Thase, M. E., Yonkers, K. A., McCullough, J. P., Keitner, G. I., Gelenberg, A. J., Thomas, S., Harrison, W. M., & Keller, M. B. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.9.1445 · Cited by 712
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–283 of 283
Emerging studies of human visceral nociceptors
Reed, D. E., & Vanner, S. J. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00391.2016 · Cited by 5
“Manipulation of the microbiome with either antibiotics (35) or probiotics (23) has had some success in IBS treatment suggesting a potential role for the microbiome in symptom generation.”
BackgroundJalanka, J., & Spiller, R. E. (2017) · Neurogastroenterology & Motility · doi:10.1111/nmo.13194 · Cited by 5
Safwat, E., Salah, M. M., & Hussein, H. A. (2020) · Arab Journal of Gastroenterology · doi:10.1016/j.ajg.2020.08.003 · Cited by 5
Die neue Leitlinie zum Reizdarmsyndrom: Was ändert sich?
von Schassen, H., Andresen, V., & Layer, P. (2021) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1331-6478 · Cited by 5
“[8] Menees SB, Maneerattannaporn M, Kim HM et al.”
BackgroundAkyuz, F., Çelebi, A., Dogan, I., Erzin, Y., Kav, T., Soytürk, M., Oğuz, D., Özer, B., & Kaymakoğlu, S. (2024) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2024.24029 · Cited by 5
The Use of Non-Narcotic Pain Medication in Pediatric Gastroenterology
Miranda, A., & Saps, M. (2014) · Pediatric Drugs · doi:10.1007/s40272-014-0080-6 · Cited by 4
Primary Care Evaluation and Management of Gastroenterologic Issues in Women.
Rao, V. L., Micic, D., & Kim, K. E. (2016) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2016.01.006 · Cited by 3
“With regard to antibiotics, rifaximin has been studied and also may provide relief in some patients but should be used with caution because symptoms may recur after completion of a 14-day course.(34) In patients who do not respond to over-the-counter symptom-based treatments or”
BackgroundPossibilities of therapeutic manipulation of the gut microbiota
Drastich, P., Bajer, L., & Kverka, M. (2018) · Vnitřní lékařství · doi:10.36290/vnl.2018.091 · Cited by 4
“Metaanalýza publi kovaná v roce 2012 ukázala, že rifaximin u pacientů s IBS byl účinnější než placebo při hodnocení globálních pří znaků a nadýmání [63].”
Stoking the Flame: The American Journal of Gastroenterology 2013
Moayyedi, P., & Chey, W. D. (2013) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.462 · Cited by 4
“Lindfors P, Unge P, Arvidsson P et al. Effects of gut-directed hypnotherapy on IBS in different clinical settings—results from two randomized, controlled trials.”
ResultInfluentialSelf-citationShah, Q., & Soldera, J. (2026) · World Journal of Methodology · doi:10.5662/wjm.v16.i1.107169 · Cited by 4
Actualidades en la fisiopatología del síndrome de intestino irritable: el papel de las infecciones
Remes-Troche, J. M. (2012) · Medicina Interna de México · Cited by 3
Normal Disaccharidase Activity and Disaccharidase Activity in Patients with Functional Enteropathies
Kondrashova, E. A., Moscow, R. F., & Parfenov, A. I. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-4-55-60 · Cited by 3
“Препараты этой группы могут временно уменьшить основные проявления СРК [46].”
Pharmacology of Antispasmodic Drugs Used in Management of Irritable Bowel Syndrome
Карева, Е. Н., & Moscow, R. F. (2021) · Doctor Ru · doi:10.31550/1727-2378-2021-20-4-46-54 · Cited by 3
Scientific Evidence for the Treatment of Children with Irritable Bowel Syndrome
Quitadamo, P., Isoldi, S., Mallardo, S., Zenzeri, L., & Nardo, G. D. (2021) · Current Pediatric Reviews · doi:10.2174/1573396317666210127123330 · Cited by 4
The Microbiome–Gut–Brain Axis and the Consequences of Infection and Dysbiosis
Bienenstock, J., Kunze, W., & Forsythe, P. (2016) · The American Journal of Gastroenterology Supplements · doi:10.1038/ajgsup.2016.12 · Cited by 4
Ford, A. (2019) · Evidence-based Gastroenterology and Hepatology 4e · doi:10.1002/9781119211419.ch20 · Cited by 3
Remes-Troche, J. M., Coss‐Adame, E., Schmulson, M. J., García‐Zermeño, K. R., Amieva‐Balmori, M., Carmona-Sánchez, R., Gomez-Escudero, O., Gómez-Castaños, P. C., Icaza-Chávez, M. E., López‐Colombo, A., et al. (2025) · Revista de Gastroenterología de México (English Edition) · doi:10.1016/j.rgmxen.2024.10.009 · Cited by 5
Alam, M., Abbas, K., Khan, M., Saini, R. S., & Faraz, M. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02317-8 · Cited by 2
Quigley, E. M. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00039-3 · Cited by 3
Oh, S. J., Tashjian, V. C., Mirocha, J., Nagar, M., Mathur, R., Lin, E. A., Chua, K. S., Rezaie, A. R., Pimentel, M., & Pichetshote, N. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5302-2 · Cited by 3
Small intestinal bacterial overgrowth: from malabsorption to misinterpretation
Quigley, E. M. M. (2025) · Minerva Gastroenterology · doi:10.23736/s2724-5985.24.03781-1 · Cited by 4
Remes-Troche, J. M., Coss‐Adame, E., Schmulson, M. J., García‐Zermeño, K. R., Amieva‐Balmori, M., Carmona-Sánchez, R., Gomez-Escudero, O., Gómez-Castaños, P. C., Icaza-Chávez, M. E., López‐Colombo, A., et al. (2025) · Revista de Gastroenterología de México · doi:10.1016/j.rgmx.2024.10.003 · Cited by 6
Mon cerveau et mon intestin communiquent, parfois mal !
Bonaz, B. L., & Sonia Pellissier, A. (2013) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2013.10.004 · Cited by 3
Modulation of the Gut Ecosystem in Irritable Bowel Syndrome
König, J., & Brummer, R. J. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_4 · Cited by 2
Are probiotics useful for the average consumer?
Lockyer, S. (2017) · Nutrition Bulletin · doi:10.1111/nbu.12247 · Cited by 2
“The authors noted that the rate of responders, numbers needed to treat and difference in responder rate values were similar to reported improvements in global irritable bowel syndrome (IBS) symptoms after treatment with the antibiotic rifaximin (Menees et al. 2012).”
ResultFocal Active Colitis Presented With Chronic Diarrhea
Mandzhieva, B., Taylor, J., Zafar, H., Rashid, M. U., & Khan, A. H. (2020) · Cureus · doi:10.7759/cureus.8140 · Cited by 2
“Banaag et al. in their multicenter retrospective study have shown that there are approximately 25% of patients presenting with diarrhea, abdominal pain and IBS with the histological finding of FAC without a definitive diagnosis.”
BackgroundResultInfluentialDarmmikrobiom und funktionelle gastrointestinale Erkrankungen
Keller, J., & Andresen, V. (2015) · Die Gastroenterologie · doi:10.1007/s11377-014-0964-6 · Cited by 2
Schoenfeld, P., & Pimentel, M. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12837 · Cited by 2
“The third RCT discussed in our study is a phase 2 dose-ranging study to identify the ideal dose for treatment of non-C IBS.(4)”
BackgroundInfluentialEditorial: safety and tolerability of rifaximin for IBS – more information is required
Cai, S., & Yang, Y. S. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12769 · Cited by 2
Videlock, E. J., & Chang, L. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch75 · Cited by 2
Modern approaches to the diagnostics and treatment of functional diarrhea
Sheptulin, A. A., & Rabotyagova, Y. S. (2022) · Clinical Medicine (Russian Journal) · doi:10.30629/0023-2149-2022-100-6-300-304 · Cited by 2
Fujikawa, Y., & Tominaga, K. (2024) · Springer eBooks · doi:10.1007/978-981-97-8410-3_11 · Cited by 1
Bach, C., Schiebel, C. S., Braga, L. L. V. D. M., Fernandes, A. C. V. U., Avancini, M., Fernandes, G. F., Zaleski, J., D'Agostin, J. B., & Ferreira, D. M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1810632 · Cited by 1
“Randomized controlled trials and meta-analyses have demonstrated modest but clinically meaningful efficacy for these therapies (Pimentel et al., 2011; Menees et al., 2012; Riddle et al., 2016).”
Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results
Lorenzetti, R., & Prantera, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.96 · Cited by 1
Woodward, K. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735483-00273 · Cited by 1
Medikamentöse Therapien bei Reizmagen und Reizdarm
Schindler, V., & Pohl, D. (2017) · Der Gastroenterologe · doi:10.1007/s11377-017-0145-5 · Cited by 1
Do You Really Want a Hunter-gatherer Microbiota? Perils and Pitfalls for Your Gut
Ruscio, M. (2017) · Journal of Evolution and Health An Ancestral Health Society Publication · doi:10.15310/2334-3591.1045 · Cited by 1
Cybulska, A. M. (2019) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2019.0043
“In the case of two episodes of recurrence in patients who have benefited from rifaximin therapy, repeated treatment according to the same regimen and with at least 4-week intervals is recommended (59,60) .”
Gut Microbiome and Gastrointestinal Disorders
Legaki, E., Karanasou, E. A., & Gazouli, M. (2021) · The microbiomes of humans, animals, plants, and the environment · doi:10.1007/978-3-030-59642-2_3 · Cited by 2
The Microbiome and Irritable Bowel Syndrome
Gleasman-DeSimone, S. (2024) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000813 · Cited by 1
Bucci, C., Santonicola, A., & Iovino, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-802189-7.00040-x · Cited by 1
Ткач, С. М., & Mirzabayeva, N. M. (2019) · Modern Gastroenterology · doi:10.30978/mg-2019-1-93 · Cited by 1
Pohl, D., Vavricka, S. R., Fox, M. R., Madisch, A., Studerus, D., Wiesel, P. H., Heinrich, H. S., Linas, I., Schoepfer, A. M., Schwizer, A., et al. (2023) · Praxis · doi:10.1024/1661-8157/a003988 · Cited by 1
Use of Oral Antibiotics in Elderly Gastrointestinal Patients
Choe, S. C., M.D., PhD., P., & Lee, D. H. (2012) · Journal of the Korean Geriatrics Society · doi:10.4235/jkgs.2012.16.3.108
VACCINATION STATUS IN CHILDREN UNDER 8 YEARS AND ATTITUDES OF THEIR PARENTS
Kut, A., & Geckil, A. (2014) · Turkish Journal of Family Medicine & Primary Care · doi:10.5455/tjfmpc.154621
Rifaximin: Irritable Bowel Syndrome
Generali, J. A., & Cada, D. J. (2014) · Hospital Pharmacy · doi:10.1310/hpj4911-1014
¿Antimicrobianos para el síndrome de intestino irritable?
Frati-Munari, A. C. (2013) · Atención Familiar · doi:10.1016/s1405-8871(16)30108-0
Opinion: Refractory inflammatory bowel disease—could it be an irritable bowel?
Meng, J., Agrawal, A. K., & Whorwell, P. J. (2013)
Management of irritable bowel syndrome in primary care
Olano, C., López‐Colombo, A., & Schmulson, M. (2013) · doi:10.2217/ebo.13.525
Functional Bowel Disorders for the Colorectal Surgeon
Ayscue, J. M., & Kumar, A. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-25970-3_62
Alvarado, B. J., Otero, R. W., Santos, M. A. J., Andrea, P., Roa, B., Andrés, G., Puentes, L. L. R., María, A., Jiménez, F., Fernando, C., et al. (2015)
Yazdani, M., Aramesh, A., Rafiei, R., Daghaghzadeh, H., & Adibi, P. (2016) · Advanced Biomedical Research · doi:10.4103/2277-9175.192737
“[2,11] Since an abnormal composition of gut microbiota exists among IBS patients, using antibiotics seems to be appropriate to treat IBS.”
BackgroundInfluentialSmall Intestinal Bacterial Overgrowth
Kim, K.-N., & Lee, S. H. (2013)
Gastrointestinal Diseases During Pregnancy
Akbari, M., & Wolf, J. L. (2017) · Springer eBooks · doi:10.1007/978-3-319-39328-5_1
Irritable bowel syndrome pharmacotherapy
Camilleri, M. (2013) · doi:10.2217/ebo.13.456
Menozzi, A., Dall’Aglio, M., Quintavalla, F., Meucci, V., & Bertini, S. (2017) · Veterinary Record Case Reports · doi:10.1136/vetreccr-2016-000423
Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)
Doffou, S., Anzouan-Kacou, K. H., Messou, E., Bangoura, D., Kouamé, D., Alassan, M. K., Assi, C., Bathaix, F. M. Y., ATTIA, A. K., & Lohoues, M. J. (2017) · Open Journal of Gastroenterology · doi:10.4236/ojgas.2017.710027
“710027 267 Open Journal of Gastroenterology five randomized controlled trials of Rifaximin for IBS-D demonstrated a significant improvement in overall SBS symptoms with Rifaximin in comparison with placebo [29] [30] [31].”
BackgroundRifaximin for Treatment of Small Bowel Bacterial Overgrowth
Owyang, C. (2018) · Current Trends in Gastroenterology and Hepatology · doi:10.32474/ctgh.2018.01.000115
“broad-spectrum antibiotic derived from rifamycin with in-vitro activity against Gram-positive, Gram-negative, and anaerobic bacteria [11,12].”
BackgroundIrritable Bowel Syndrome: Current and Emerging Therapies
Starkweather, A. R. (2019) · Topics in Pain Management · doi:10.1097/01.tpm.0000579832.72003.7e
Bloating and Abdominal Distention
Houghton, L. A., & Ford, A. C. (2019) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.66003-8
Microbiote et syndrome de l’intestin irritable : que faut-il savoir ? Perspectives thérapeutiques
Bazin, T. (2020) · Côlon & Rectum · doi:10.3166/cer-2020-0141
Intestinal microbiota at functional intestinal disorders and celiac disease
Губергриц, Н. Б., Byelyayeva, N. V., Klochkov, O. Y., Фоменко, П. Г., Rachmetova, V. S., Цыс, А. В., & Voronin, K. O. (2020) · Modern Gastroenterology · doi:10.30978/mg-2020-4-51
Ткач, С. М., Dorofeev, A. E., & Kuzenko, Y. G. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-1-38
Ткач, С. М., Dorofeev, A. E., & Kuzenko, Y. G. (2021) · Modern Gastroenterology · doi:10.30978/mg-2021-2-21
Choe, S. C., & 이동호 (2012)
Soifer, L., Tawil, J., Rey, A., Solé, L., & Bernstein, S. (2021) · Acta gastroenteorológica latinoamericana/Acta gastroenterológica latinoamericana · doi:10.52787/kksx5531
“Carbón 24,53% (13) 14,2-38,6 17,13% (43) 12,8-22,5 0,5 Tabla 2.”
Small Bowel Intestinal Overgrowth (SIBO): A Gender Specific Hormone Disease
Lichten, E. M. (2021) · Journal of Inflammatory Bowel Diseases & Disorders
Rifamixin for the treatment of IBS
(2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.233
Ahmed, M., Khalil, K., Eida, M. M., & Salem, A. (2022) · Afro-Egyptian Journal of Infectious and Endemic Diseases · doi:10.21608/aeji.2022.136572.1223
Is Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) a Myth?
Habba, S. F. (2022) · Medical Research Archives · doi:10.18103/mra.v10i8.2975
Irritable bowel syndrome – modern ways of treatment
Kuciński, J., Fryska, Z., Wołejko, A., KULIK, K., Semeniuk, P., Matusz, K., Burczyk, R., & Górna, N. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.16.01.005 · Cited by 1
Bacterial overgrowth in irritable bowel syndrome: prevalence, diagnosis, and treatment. Review
Ткач, С. М., & Dogotar, V. B. (2023) · Modern Gastroenterology · doi:10.30978/mg-2023-3-68
Habiboğlu, İ., Sargın, Z. G., Uğurlu, C., Bostan, M. S., Haytaoğlu, M. G., Baş, B., Öztürk, O. U., Öztürk, U. K., Küçükdemirci, Ö., Yurdacan, M., et al. (2022) · Akademisyen Kitabevi eBooks · doi:10.37609/akya.1345
Role of the gut microbiota in aging and maintenance of active longevity. Part 2
Константиновна, Р. А., Ashikhmin, Y. I., Ratnikov, V. A., Grudina, М., & Dikur, O. (2024) · Vrach · doi:10.29296/25877305-2024-02-03
Hazan, S., Bao, G., Vidal, A., & Sfera, A. (2024) · Cureus · doi:10.7759/cureus.75884
“Corticosteroids have no proven efficacy in maintaining remission [7] and in IBS patients, rifaximin has only modest benefits over placebo [8,9].”
Healthy gut: A wellness factor for humans
Das, M., Santra, S., Khamaru, D., Jayaseelan, P., Lalsangi, S. B., & Banerjee, R. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33351-4.00010-6
Chean, K.-Y. (2025) · Springer eBooks · doi:10.1007/978-981-97-7640-5_29
Personalized gastroenterology: Irritable Bowel Syndrome
Acharya, R., & Kumari, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40483-2.00003-0
The Gut-Brain Axis—From Science to Clinical Practice
Quigley, E. M. M. (2026) · Gastro Hep Advances · doi:10.1016/j.gastha.2026.100975
Al-Qurain, A. A., Abdelrahman, A., Alzahib, I. H., Alsinan, Z. A., Edrissy, A. A., Alkhalil, A. O., Jamor, O. A., AlAhmari, Y. A., Almohmmadi, O. A., Alrehaili, A. A., et al. (2026) · Cureus · doi:10.7759/cureus.116820
Metadata
- Authors
- Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D.
- Affiliations
- Michigan Medicine (US)
- Corresponding author
- Chey, William D
- Venue
- American Journal of Gastroenterology
- Published
- 2012-01
- Volume
- 107
- Issue
- 1
- Pages
- 28-35
- ISSN
- 0002-9270 (ISSN-L)
- OpenAlex
- W2049004338
- Cited by
- 283
- References
- 58
- Citations by year
- 2026: 6 · 2025: 10 · 2024: 11 · 2023: 12 · 2022: 13 · 2021: 20 · 2020: 21 · 2019: 13 · 2018: 24 · 2017: 24 · 2016: 29 · 2015: 27 · 2014: 39 · 2013: 21 · 2012: 12
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- rifaximin, irritable bowel syndrome, bloating, treatment efficacy, tolerability, cumulative dose, subgroup analysis, publication bias, number needed to treat, subgroup heterogeneity
- MeSH terms
- Rifaximin, Anti-Infective Agents, Humans, Rifamycins, Randomized Controlled Trials as Topic, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
